Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

Figure 3 Relationship between tuftelin 1 expression and prognosis of hepatocellular carcinoma. A: Kaplan-Meier analysis was performed to compare the overall survival (OS) between hepatocellular carcinoma (HCC) with high (n = 66) and low (n = 66) TUFT1; A1: The high (n = 19) and low (n = 40) tuftelin 1 (TUFT1) with OS at early HCC; A2: The high (n = 47) and low (n = 26) TUFT1 with OS at advanced HCC; B: Kaplan-Meier analysis was performed to compare the disease-free survival (DFS) between HCC with high (n = 66) and low (n = 66) TUFT1; B1: The high (n = 19) and low (n = 40) TUFT1 with DFS at early HCC; B2: The high (n = 47) and low (n = 26) TUFT1 with DFS at advanced HCC.